Why This Matters ~ SBRT is now considered a standard treatment of care for prostate cancer based on high level studies including:
The HYPO-RT-PC study is a landmark Scandinavian phase 3 clinical trial that established ultra-hypofractionated radiotherapy (a very short, high-dose course) as a safe and effective standard-of-care option for men with intermediate-to-high-risk localized prostate cancer.
The PACE-B (Prostate Advances in Comparative Evidence) study is an international phase III clinical trial that established Stereotactic Body Radiotherapy (SBRT) as a new standard of care for men with low-to-intermediate-risk localized prostate cancer. The study demonstrated that a highly concentrated 5-day treatment course (SBRT) is just as effective as traditional radiotherapy schedules lasting 4 to 8 weeks.
UCLA-LED GENERAL CONSORTIUM STUDY
The UCLA-led “general consortium study” refers to a massive, international, multi-institutional study led by Dr. Amar Kishan at UCLA Health Jonsson Comprehensive Cancer Center that analyzed the outcomes of 2,142 men with low-intermediate-and high-risk localized prostate cancer treated with Stereotactic Body Radiation Therapy (SBRT) between 2000 and 2012.
Key Aspects of the Study:
Purpose: To assess the long-term safety and efficacy of SBRT (high-dose radiation in five or fewer sessions) in a real-world, pooled cohort, given that earlier data was limited to smaller studies.
Findings: The study found low rates of toxicity and high efficacy (cancer control) with a median follow-up of nearly 7 years.
Significance: This, along with other studies led by UCLA, helped establish SBRT as a standard-of-care, non-invasive treatment option for low- to intermediate-risk prostate cancer, reducing treatment time from several weeks to just one week.
High-Risk Study: In 2021, Dr. Kishan led another consortium study on 344 patients with high-risk prostate cancer, proving SBRT to be safe and effective for this group, which was published in JAMA Oncology.
MIRAGE Trial: A randomized study demonstrating that MRI-guided SBRT reduces long-term side effects compared to CT-guided SBRT.
Post-Surgery SBRT: UCLA researchers also studied SBRT for recurrent prostate cancer after surgery (prostatectomy), finding it a safe, shorter, and effective option.
UCLA-LED SHARP CONSORTIUM (HIGH RISK DISEASE)
The UCLA-led SHARP Consortium (Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate) is an international research group that validated a shortened, high-intensity radiation treatment for aggressive prostate cancer.
The consortium’s primary findings, led by Dr. Amar Kishan at UCLA Health, established that Stereotactic Body Radiotherapy (SBRT) is a safe and effective “standard of care” option for high-risk patients.
Key Findings and Impact
Reduced Treatment Time: The study proved that a traditional 45-day radiation course can be safely condensed into just 5 days.
High Efficacy: Analysis of 344 patients showed a 4-year cure rate of 82% (biochemical recurrence-free survival) for those with high-risk disease.
Low Toxicity: Severe side effects were rare, with only about 2% of patients experiencing long-term urinary issues and less than 1% experiencing bowel issues.
Combined Therapy: The research indicated that combining SBRT with Androgen Deprivation Therapy (ADT) further improves outcomes for high-risk cases.
Why This Matters
Prior to this consortium’s work, SBRT was primarily used for low-to-intermediate risk prostate cancer. The SHARP data provided the largest evidence base to date, published in the International Journal of Radiation Oncology, allowing high-risk patients to access this more convenient, non-invasive treatment.
What Exactly is CyberKnife and SBRT? CyberKnife is an advanced form of stereotactic body radiation therapy (SBRT) that utilizes cutting-edge imaging and AI missile guided robotic technology to deliver precise, high-dose radiation directly to cancerous tumors, destroying them with minimal impact on surrounding healthy tissue and vital organs.
Why Is CyberKnife Recommended for Prostate Cancer? CyberKnife is highly recommended for prostate cancer patients due to its ability to deliver high doses of radiation with sub-millimeter accuracy. This method greatly reduces the number of radiation treatments necessary to just 5 over 10 days, instead of 42 over 3 months with other types of radiation therapy.
How Effective is CyberKnife in Treating Prostate Cancer? CyberKnife has demonstrated high effectiveness in treating prostate cancer, with many patients achieving positive outcomes and long-term remission. The success of the treatment depends on various factors, including the stage and grade of the cancer, but overall, CyberKnife offers a highly effective option for many patients.
Is CyberKnife Invasive? No, CyberKnife is entirely non-invasive. Its missile guided technology continuously tracks the tumor’s movement, allowing the radiation beams to adjust automatically if the tumor moves, which they do naturally as ther is constant movement inside our bodies, no matter how still you are laying on the CyberKnife treatment table.
What Should You Expect? Before treatment begins, small markers called fiducials are placed around your prostate to accurately define the treatment area. You may also receive a SpaceOAR hydrogel injection to protect the rectum from radiation exposure. A CT scan, and potentially an MRI or PET scan, will be performed to guide the treatment planning.
During the CyberKnife sessions, the robotic system delivers precise radiation while constantly adjusting to any movement of your prostate. Each treatment typically lasts between 30 minutes, depending on the size and location of the tumor.
How Does CyberKnife Work in Treating Prostate Cancer? CyberKnife works by continuously monitoring the position of your prostate and the tumor, allowing for real-time adjustments in the radiation beams. Its a precise high dose radiation treatment that can kill the prostate cancer cells, therefore controlling and curing the prostate cancer.
What Are the Advantages of CyberKnife Over Other Prostate Cancer Treatments? The primary advantage of CyberKnife is its exceptional precision, which significantly reduces the risk of side effects and damage to surrounding healthy tissues.
What Are the Potential Side Effects of CyberKnife Treatment? Common side effects may include fatigue, urinary symptoms, and changes in bowel habits. Most of these side effects are temporary and typically resolve a few days or weeks after the completion of treatment. Over the counter medications can usually eliminate any side effects, or medications your doctor can prescribe.
What is the Typical Treatment Schedule for CyberKnife? The treatment schedule for CyberKnife is 5 therapy sessions, usually one given every other day. The exact number of sessions will depend on your specific cancer characteristics and treatment plan.
For more information or to set up a consultation, call the CyberKnife Center of Miami at 305-279-2900.